Immunogenicity of the recombinant GenHevac B Pasteur vaccine against hepatitis B in chronic uremic patients.
Immunogenicity of the recombinant GenHevac B vaccine (G), containing both the S and the preS2 antigen, was compared with that of the plasma-derived Hevac B (H) vaccine in 120 chronic uremic predialysis patients.
Sixty received 20 mug/dose of G and 60 received 5 mug/dose of H at 0, 1, 2, 4, and 12 months.
Two months after the fourth injection, seroconversion (antibody to hepatitis B surface antigen [HBs], >=2 mIU/mL) was seen in 85% of group G and 67% of group H patients (P<.02); seroprotection (anti-HBs, >=10 mIU/mL) was seen in 71% and 59%, respectively.
The geometric mean titers (GMT) of anti-HBs in responders were 112 and 229 mIU/mL, respectively.
Mots-clés Pascal : Hépatite virale B, Virose, Infection, Chronique, Vaccination, Insuffisance rénale, Evaluation, Prévention, Immunoprophylaxie, Immunogénicité, Vaccin, Homme
Mots-clés Pascal anglais : Viral hepatitis B, Viral disease, Infection, Chronic, Vaccination, Renal failure, Evaluation, Prevention, Immunoprophylaxis, Immunogenicity, Vaccine, Human
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 94-0443680
Code Inist : 002B05C02G. Création : 199406.